medigraphic.com
ISSN 0210-5187 (Digital)

2006, Número 1

<< Anterior Siguiente >>

Med Cutan Iber Lat Am 2006; 34 (1)


Síndrome de hipersensibilidad a sulfasalacina en paciente VIH

Corral CM, Arranz SD, Herranz PP, Díaz DR, Martín DMA, Casado JM

Idioma: Español
Referencias bibliográficas: 28
Paginas: 17-20
Archivo PDF: 207.64 Kb.


RESUMEN

El síndrome de hipersensibilidad a fármacos se define por la triada clínica de fiebre, erupción cutánea y afectación de órganos internos.
Múltiples fármacos se asocian con sintomatología cutánea aislada (exantema o erupción maculopapulosa), mientras que sólo unos pocos fármacos se asocian con el síndrome de hipersensibilidad. Fármacos relacionados con este síndrome son los anticonvulsivantes, antibióticos, sulfasalazinas y antirretrovirales.
A pesar de las múltiples reacciones medicamentosas descritas en estos pacientes, este es el primer caso de síndrome de hipersensibilidad a sulfasalazina en un paciente con infección por el VIH que se recoge en la literatura dermatológica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Pérez Pimiento AJ, Calvo Manuel E, Lozano Tonkin C, Espinós Pérez D. Síndrome de hipersensibilidad retardada a fármacos. Rev Clin Esp 2002;202:339-46.

  2. Spielberg SP, Shear NH, Cannon M, Hutson NJ, GudersonK. In vitro assesment of a hypersensitivity syndrome associated with sorbinel. Ann Intern Med 1991;114:720-4.

  3. Schlienger R, Shear N. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998;39:S3-7.

  4. Coopman SA, Johnson RA, Platt R, Stern R. Cutaneous disease and drugs reactions in HIV infection. N Engl J Med 1993;328:1670-4.

  5. Koopmans PP, Van der ven AJAM, Vreet B, Van der Meer JWM. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic?. AIDS 1995;9:217-22.

  6. Burman W, Orr L. Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz. AIDS 2000;14:2793-4.

  7. Fuentes A, Otero MJ. Interacciones de los fármacos antirretrovirales. Med Clin (Barc) 1999;113:94-102.

  8. Pakianathan MR, Kamarulzaman A, Ismail R, Mc Millan A, Scott GR. Hypersensitivity reactions to high-dose co-trimoxazole in HIV-infected Malaysian and Scottish patients. AIDS 1999;13:1787-8.

  9. Beller TC, Boyce JA. Prolonged anticonvulsant hypersensitivity syndrome related to lamotrigine in patient with HIV. Allergy Asthma Proc. 2002;23:415-9.

  10. Sissoko D, Ajana F, de la Tribonniere X, Baclet V, Monton Y. Cutaneous, hepátic and hematologic manifestations due to nevirapine: DRESS síndrome?. Presse Med. 2000;29:1014-2.

  11. Sibaud V, Billon C, Barcat D, Bernard N, Geniaux M. Hypersensitivity syndrome to nevirapine. Therapie 2000;55:320-2.

  12. Fernandez-Chico N, Bielsa Marsal I. Síndrome de hipersensibilidad a fármacos. Piel 2003;18:252-8.

  13. Hewitt RG. Abacair hipesensitivity reaction. CID 2002;34:1137-42.

  14. Wassef M, Keiser P. Hypersensitivity to zidovudine: report of a case of anaphylaxis and review of the literature. Clin Infect Dis 1995;20:1387-9.

  15. Herranz P, Fernández-Díaz ML, Lucas R, González García J, Casado M. Cutaneous vaculitis associated with didanosine. Lancet 1994;344:680.

  16. Tancrede-Bohin E, Range F, Bournerias I, Roujeau JC, Guillaume JC. Hypersensitivity syndrome associated with zalcitabine therapy. Lancet 1996;347:971.

  17. Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, et al: Delavirdine susceptibilities and associated reverse transcriptase mutations in human immuno-deficiency virus type 1 isolates from patients in a phaseI/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother 2000;44:794-7.

  18. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated withneirapine therapy. Clin Infect Dis 1998;27:1321-2.

  19. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efairenz therapy. Clin Infect Dis 2000;30:227-8.

  20. Goodgame JC, Pottage JC Jr, Jablonowski H, Hardy WD, Stein A, Fischl M, et al. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1 infected antiretroviral naïve adults. Antivir Ther 2000;5:215-25.

  21. Muñoz Fernández S, Hidalgo V, Fernández-Melón J, Schlincker A, Bonilla G, Ruiz-Sancho D, Fonseca A, Gijón-Baños J, Martín-Mola E. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one year period. J Rheumatol 2003;30:1277-9.

  22. Borrás-Blasco J, Navarro-Ruiz A, Matarredona J, Devesa P, Montesinos-Ros A, González-Delgado M. Photo-induced stevens-johnson syndrome due to sulfasalazine therapy. Ann Phamacother 2003;37;1241-43.

  23. Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS. Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine. Am J Gastroenterol 1986;81:205-8.

  24. Marinos G, Riley J, Painter DM, McCaughan GW. Sulfasalazine-induced fulminant hepatic failure. J Clin Gastroenterol. 1992;14:132-5.

  25. Kunisaki Y, Goto H, Kitagawa K, Nagano M. Salazosulfapyridine induced hypersensitivity syndrome associated with reactivation of humanherpes virus 6. Intern Med. 2003;42:203-7.

  26. Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, Belaich S, Crickx B. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms.

  27. Tohyama M, Tahaa Y, Yasukawa M, Inagi R, Urano Y, Yamanishi K, Hashimoto K. Severe hypersensitivity síndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 1998;134:1113-7.

  28. Ohtani T, Hiroi A, Sakurane M, Furukawa F. Slow acetylator genotypes as a possible risk factor for nfectious mononucleosis-like syndrome induced by salazosulfapyridine. Br J Dermatol 2003;148:1035-9.




2020     |     www.medigraphic.com